Author: Sánchez-Montalvá, Adrián; Sellarés-Nadal, Júlia; Espinosa-Pereiro, Juan; Fernández-Hidalgo, Nuria; Pérez-Hoyos, Santiago; Salvador, Fernando; Durà , Xavier; Miarons, Marta; Antón, Andrés; Eremiev-Eremiev, Simeón; Sempere-González, Abiu; Monforte-Pallarés, Arnau; Bosch-Nicolau, Pau; Augustin, Salvador; Sampol, Júlia; Guillén-del-Castillo, Alfredo; Almirante, Benito
Title: Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab Cord-id: nypub6ns Document date: 2021_6_18
ID: nypub6ns
Snippet: BACKGROUND: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. METHODS: We report the preliminary results from the Vall d’Hebron cohort study at Vall d’Hebron University Hospital, in Barcelona (Spain), including all c
Document: BACKGROUND: Modulation of the immune system to prevent lung injury is being widely used against the new coronavirus disease (COVID-19). The primary endpoint was mortality at 7 days after tocilizumab administration. Secondary endpoints were admission to the intensive care unit, development of ARDS and respiratory insufficiency among others. METHODS: We report the preliminary results from the Vall d’Hebron cohort study at Vall d’Hebron University Hospital, in Barcelona (Spain), including all consecutive patients who had a confirmed SARS-CoV-2 infection and who were treated with tocilizumab until March 25th. RESULTS: 82 patients with COVID-19 received at least one dose of tocilizumab. The mean (± SD) age was 59.1 (19.8) years, 63% were male, 22% were of non-Spanish ancestry, and the median (IQR) age-adjusted Charlson index at baseline was 3 (1–4) points. Respiratory failure and ARDS developed in 62 (75.6%) and 45 (54.9%) patients, respectively. Median time from symptom onset to ARDS development was 8 (5–11) days. Mortality at 7 days was 26.8%. Hazard ratio for mortality was 3.3; 95% CI, 1.3–8.5 (age-adjusted hazard ratio for mortality 2.1; 95% CI, 0.8–5.8) if tocilizumab was administered after the onset of ARDS. CONCLUSION: Early administration of tocilizumab in patients needing oxygen supplementation may be critical to patient recovery. Our preliminary data could inform bedside decisions until more data regarding the precise timing in of initiation of the treatment with tocilizumab.
Search related documents:
Co phrase search for related documents- absolute number and acute kidney injury: 1
- absolute number and acute lung injury: 1
- absolute number and acute myocardial infarction: 1, 2
- absolute number and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- absolute number and acute sars cov respiratory syndrome coronavirus: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- acei enzyme inhibitor and acute ards respiratory distress syndrome: 1
- acei enzyme inhibitor and acute kidney injury: 1
- acei enzyme inhibitor and acute respiratory syndrome: 1, 2, 3, 4, 5
- acei enzyme inhibitor and acute sars cov respiratory syndrome coronavirus: 1, 2, 3
- active solid cancer and acute respiratory syndrome: 1
- active solid cancer and acute sars cov respiratory syndrome coronavirus: 1
- acute ards respiratory distress syndrome and additional treatment: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and administration tocilizumab: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute ards respiratory distress syndrome and admission evaluate: 1, 2
- acute ards respiratory distress syndrome and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute ards respiratory distress syndrome cause and administration tocilizumab: 1
- acute kidney injury and additional treatment: 1, 2, 3, 4
- acute kidney injury and admission level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute kidney injury and admission perform: 1
Co phrase search for related documents, hyperlinks ordered by date